However, the successful inhibition of this pathway using BRAF/MEK inhibitors has yielded clinically relevant benefits, leading to the establishment of these agents as standard treatment options for malignant melanoma and non-small cell lung cancer. Here, BRAF is linked to non-small cell lung carcinoma.